Tesamorelin

Potential Benefits of Tesamorelin

• Promotes fat loss [1-9]
• Improves cognitive function [10-19]
• Improves lipid profile [1, 9, 20-23]
• Improves liver health [24-26]
• Lowers blood sugar levels [9, 27]
• Lowers the risk of cardiovascular disease [1, 21, 28]
• Treats nerve injury [29]

What is Tesamorelin?

Tesamorelin is an FDA-approved drug for lipodystrophy, a medical condition characterized by an abnormal distribution of body fat. This small molecule (known as peptides) is a synthetic analog of growth hormone–releasing factor, which means that it stimulates the pituitary gland to secrete growth hormone (GH). This mechanism is thought to play an integral role in body fat reduction since direct GH administration has fat-burning effects.

How Tesamorelin Works?

Tesamorelin stimulates the synthesis and release of GH by acting on the pituitary cells in the brain. The increase in GH also increases the levels of insulin-like growth factor (IGF-1). This, in turn, stimulates muscle growth and fat loss. The promotion of muscle growth by Tesamorelin can be beneficial for individuals seeking to enhance their physical performance or improve their body composition. With consistent use and a proper exercise regimen, Tesamorelin can support significant muscle growth over time. However, it’s essential to note that tesamorelin, like any medication, may have unwanted effects, and individuals should discuss these potential side effects with their healthcare provider before starting treatment.

Chemical Structure of Tesamorelin

Research on Tesamorelin

Promotes Fat Loss

Fat reduction is the major benefit of tesamorelin. In fact, the US Food and Drug Administration approved tesamorelin last November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Several lines of evidence clearly support this fat-burning effect:

1. In HIV patients with central fat accumulation, subcutaneous injection of tesamorelin at a dose of 2 mg was generally well tolerated and resulted in sustained decrease in visceral adipose tissue (active component of total body fat). [1]
2. A 2010 study published in the Journal of Acquired Immune Deficiency Syndromes found that tesamorelin reduced visceral fat (body fat stored within the abdominal cavity) by approximately 18% and improved body image distress in HIV-infected patients with central fat accumulation. [2]
3. A 2011 study published in HIV/AIDS – Research and Palliative Care has shown that tesamorelin is safe and effective in reducing central fat accumulation among HIV-infected patients.[3]
4. In HIV patients with abdominal adiposity, tesamorelin reduced visceral adipose tissue by increasing adiponectin, a protein that breaks down fat. [4]
5. In patients with HIV-related lipodystrophy, 52 weeks of tesamorelin treatment reduced abdominal fat. [5]
6. A 2015 study published in PLoS One Journal found that patients with baseline metabolic syndrome, elevated triglyceride levels, or white race were most likely to experience reductions in visceral adipose tissue following 6 months of tesamorelin treatment. [6]
7. In HIV-infected patients with excess abdominal fat, treatment with tesamorelin reduced visceral adipose tissue and maintained the reduction for up to 52 weeks. [7]
8. In HIV-infected patients with abdominal fat accumulation, daily tesamorelin treatment for 26 weeks decreased visceral fat by 15.2% compared to placebo. [8]
9. In HIV-infected patients receiving tesamorelin, reduction in visceral adipose tissue was accompanied by improvement in metabolic profile. [9]

Improves Cognitive Function

Growth hormone–releasing hormone (GHRH) such as tesamorelin has potent effect on brain function. Studies show that this “cognitive enhancer” may benefit people with age-related memory problems and those suffering from chronic, progressive mental deterioration:

1. In older adults with memory impairment, short-term tesamorelin administration improved executive function and verbal memory. [10]
2. Daily subcutaneous injections of tesamorelin for 20 weeks improved executive function, verbal memory, and visual memory in both adults with mild cognitive impairment and healthy older adults. [11]
3. In patients with mild cognitive impairment, tesamorelin administration at a dose of 1mg/day for 10 weeks improved various areas of cognition. [12]
4. A 2012 study published in Nature Reviews Endocrinology found that tesamorelin administration in patients with age-related cognitive impairment significantly improved memory and thinking skills. [13]
5. In adults with mild cognitive impairment, daily subcutaneous injections of tesamorelin increased GH levels and improved executive function and verbal memory. [14-15]
6. In normal older adults and adults with mild cognitive impairment, tesamorelin administration for 5 months demonstrated favorable effects on cognition. [16]
7. Self-administration of tesamorelin at 1 mg 30 minutes before bedtime slowed cognitive decline in older adults. [17]
8. An ongoing Phase II trial of tesamorelin for cognition in aging HIV-infected persons shows promising results with the tesamorelin-treated group exhibiting improvement in neurocognitive performance. [18]
9. In adults with mild cognitive impairment, administration of daily subcutaneous injections of tesamorelin significantly increased the levels of gamma-Aminobutyric acid (GABA), a neurotransmitter that facilitates brain cell communication. [19]

Improves Lipid Profile

The ability of tesamorelin to improve lipid profile can be attributed to its fat-burning effect and GH-boosting properties. High-quality studies support its beneficial effect on triglycerides, total cholesterol, low-density lipoprotein (bad cholesterol), and high-density lipoprotein (good cholesterol):

1. In HIV patients with abdominal fat accumulation, subcutaneous injection of tesamorelin at a dose of 2 mg significantly improved triglycerides and total cholesterol levels. [1]
2. The administration of tesamorelin in HIV-infected patients resulted in greater reduction in triglycerides compared to placebo treatment. [9]
3. Treatment of type 2 diabetic patients with tesamorelin for 12 weeks significantly reduced total cholesterol and low-density lipoprotein. [20]
4. In HIV-infected patients with excess abdominal fat, tesamorelin treatment increased the levels of high-density lipoprotein. [21]
5. In patients with HIV, a daily subcutaneous injection of tesamorelin resulted in decreased visceral fat and improved lipid profiles. [22-23]

Improves Liver Health

Studies also show that tesamorelin may benefit liver function through various important mechanisms:

1. In HIV-infected men and women with hepatic steatosis (accumulation of fat in the liver), treatment with tesamorelin for 12 months significantly reduced liver fat. [24]
2. In HIV-infected patients with abdominal obesity who received tesamorelin, a clinically significant reduction in body fat was associated with improved liver enzymes. [25]
3. In obese subjects with reduced GH, 12 months of tesamorelin treatment led to a significantly greater increase in phosphocreatine, a substance that protects the liver from low levels of oxygen and impaired blood flow. [26]

Lowers Blood Sugar Levels

Clinical trials also show that tesamorelin can bring down high blood sugar levels by promoting fat loss:

1. The administration of tesamorelin in HIV-infected patients did not only promote abdominal fat loss but also reduce blood sugar levels after 52 weeks of treatment. [9]
2. Tesamorelin treatment for 26 weeks also reduced blood sugar levels in HIV-infected patients with excess abdominal fat. [27]

Tesamorelin, classified as a synthetic GHRH, demonstrates promising effects beyond fat reduction, including the potential to improve metabolic parameters like blood sugar levels.

Tesamorelin, as a synthetic GHRH, exhibits multifaceted benefits beyond fat reduction, including the potential to improve metabolic parameters like blood sugar levels.

Lowers the Risk of Cardiovascular Disease

Evidence suggests that tesamorelin can help reduce the risk of cardiovascular diseases by improving various health parameters such as triglyceride levels and total cholesterol levels. [1] Tesamorelin also has the ability to raise the levels of high-density lipoprotein (good cholesterol). [21] An increase in HDL cholesterol is associated with significant cardiovascular disease risk reduction. [28] These effects indicate that tesamorelin may contribute to a lower risk of cardiovascular events and promote overall heart health.

Treats Nerve Injury

Nerve injury is one of the most debilitating medical conditions and perhaps one of the most difficult to treat as it can lead to permanent impairment in motor and sensory function of the affected area. Research, however, suggests that growth hormone-based therapies such as tesamorelin treatment can speed up the rate of healing of damaged nerves. [29]

Associated Side Effects of Tesamorelin

Tesamorelin side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on tesamorelin. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of tesamorelin. Despite this, it was listed as a side effect associated with tesamorelin even though these associated side effects are very uncommon.

Side effects associated with tesamorelin may include the following:

• Difficulty breathing
• Dizziness
• Elevations in blood sugar levels
• Fast heartbeat
• Hives
• Irritation or itching
• Joint pain
• Night sweats
• Numbness
• Rash
• Swelling of the face and throat
• Vomiting

Tesamorelin Tablets

Tesamorelin tablets represent a significant advancement in the field of peptide therapy, offering a convenient and effective way to administer this synthetic peptide. Developed to mimic the effects of growth hormone-releasing hormone (GHRH), Tesamorelin tablets stimulate the pituitary gland to produce and release growth hormone (GH). This mechanism of action makes them particularly promising in addressing conditions characterized by growth hormone deficiency or dysregulation, such as HIV-associated lipodystrophy.

One of the key advantages of Tesamorelin tablets is their ease of use and portability, providing patients with a convenient method of receiving treatment. Unlike traditional injectable forms of peptide therapy, which may require frequent administration and careful handling, Tesamorelin tablets offer a more user-friendly option. This can improve patient adherence to treatment regimens and enhance overall treatment outcomes.

Furthermore, Tesamorelin tablets have shown promising results in clinical studies for reducing excess abdominal fat, a common concern in individuals with HIV-associated lipodystrophy. By targeting visceral adipose tissue, Tesamorelin tablets have the potential to improve body composition and metabolic health in this patient population. Overall, Tesamorelin tablets represent a valuable therapeutic option for individuals seeking to address growth hormone deficiency and related conditions in a convenient and effective manner.

Tesamorelin vs Sermorelin

Tesamorelin and Sermorelin are both synthetic peptides designed to stimulate the release of growth hormone (GH) by mimicking the effects of growth hormone-releasing hormone (GHRH). While they share a common mechanism of action, there are key differences between the two peptides that may influence their suitability for different therapeutic applications. Tesamorelin is specifically indicated for the treatment of excess abdominal fat in individuals with HIV-associated lipodystrophy, whereas Sermorelin is often used more broadly for the management of growth hormone deficiency and related conditions. Tesamorelin has been shown to increase adiponectin concentrations, a protein associated with improved metabolic health, although the effects of Sermorelin on adiponectin levels are less well-documented.

One significant difference between Tesamorelin and Sermorelin is their respective formulations and routes of administration. Tesamorelin is available in tablet form, providing a convenient and easily administered option for patients. In contrast, Sermorelin is typically administered via subcutaneous injection, which may be less convenient for some individuals. The differences in formulation and administration route may impact patient preference and adherence to treatment. While Tesamorelin tablets offer a user-friendly option, the inconvenience of subcutaneous injections with Sermorelin may lead to reduced compliance, potentially resulting in poorer treatment outcomes and obvious cardiometabolic consequences.

Another consideration when comparing Tesamorelin and Sermorelin is their safety and efficacy profiles. While both peptides have demonstrated effectiveness in stimulating GH release, they may vary in terms of side effects and tolerability. Clinical studies have shown that Tesamorelin is generally well-tolerated, with the most common side effects being mild and transient. Sermorelin has also been shown to have a favorable safety profile, but individual responses may vary. Ultimately, the choice between Tesamorelin and Sermorelin will depend on factors such as the specific indication for treatment, patient preferences, and individual response to therapy. The pulsatile release of growth hormone induced by these peptides may also influence their safety and efficacy profiles, as variations in GH levels could impact physiological processes and contribute to different side effect profiles.

Tesamorelin vs Ipamorelin

Tesamorelin and Ipamorelin are both synthetic peptides with similar but distinct mechanisms of action in stimulating the release of growth hormone (GH). Tesamorelin specifically mimics the action of growth hormone-releasing hormone (GHRH) by activating the GHRH receptor, leading to increased GH secretion from the pituitary gland. In contrast, Ipamorelin acts as a selective ghrelin receptor agonist, indirectly stimulating GH release by activating the ghrelin receptor. While both peptides ultimately result in elevated GH levels, their pathways of action differ, which may influence their clinical applications and side effect profiles.

One key difference between Tesamorelin and Ipamorelin is their selectivity for specific receptors in the body. Tesamorelin targets the GHRH receptor, which is primarily involved in regulating GH release, while Ipamorelin targets the ghrelin receptor, which plays a role in appetite regulation and energy balance in addition to GH secretion. As a result, Tesamorelin may have a more targeted effect on GH secretion, whereas Ipamorelin’s action on the ghrelin receptor may lead to additional effects on appetite and metabolism.

Another consideration when comparing Tesamorelin and Ipamorelin is their respective safety and tolerability profiles. Clinical studies have demonstrated that both peptides are generally well-tolerated, with few adverse effects reported. However, individual responses to treatment may vary, and side effects such as injection site reactions, headache, and gastrointestinal symptoms have been reported with both Tesamorelin and Ipamorelin. Ultimately, the choice between Tesamorelin and Ipamorelin will depend on factors such as the specific indication for treatment, patient preferences, and individual response to therapy.

Tesamorelin Peptide Dosage

Tesamorelin peptide dosage typically varies depending on the specific medical condition being treated and individual patient factors. For the management of excess abdominal fat in individuals with HIV-associated lipodystrophy, the recommended dosage of Tesamorelin is typically 2 mg administered once daily via subcutaneous injection. It’s important for patients to follow the dosage instructions provided by their healthcare provider to ensure optimal treatment outcomes and minimize the risk of adverse effects.

The dosage of Tesamorelin may be adjusted based on factors such as the patient’s response to treatment, overall health status, and any underlying medical conditions. Healthcare providers may monitor patients regularly during treatment to assess the effectiveness of Tesamorelin therapy and make any necessary dosage adjustments as needed. Additionally, patients should not exceed the prescribed dosage of Tesamorelin or alter their treatment regimen without consulting their healthcare provider.

As with any medication, it’s crucial for patients to adhere to the prescribed Tesamorelin dosage and administration schedule to achieve the desired therapeutic effects. Patients should also report any potential side effects or concerns to their healthcare provider promptly. By following the recommended dosage and guidance from their healthcare provider, patients can optimize the benefits of Tesamorelin therapy while minimizing the risk of adverse reactions. This adherence helps maintain a consistent blood level of the medication, ensuring its efficacy in targeting visceral fat and enhancing muscle tone.

References

1. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28.
2. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune DeficSyndr. 2010;53(3):311-22.
3. Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011;3:69–79. doi:10.2147/HIV.S14561.
4. Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-8.
5. Available from http://i-base.info/htb/2092.
6. Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10):e0140358. Published 2015 Oct 12. doi:10.1371/journal.pone.0140358.
7. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J ClinEndocrinolMetab. 2010;95(9):4291-304.
8. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
9. Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54:1642–1651.
10. Available from https://www.alzheimersanddementia.com/article/S1552-5260(11)01582-2/abstract.
11. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9.
12. Available from https://clinicaltrials.gov/ct2/show/NCT02553603.
13. Mclarnon A. Neuroendocrinology: Tesamorelin can improve cognitive function. Nat Rev Endocrinol. 2012;8(10):568.
14. Available from https://www.healio.com/psychiatry/alzheimers-disease-dementia/news/print/endocrine-today/%7B9a3378b6-43ea-46c6-8d81-330a0bec5175%7D/growth-hormone-releasing-hormone-had-positive-effect-on-cognition.
15. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27:318-323.
16. Baker LD, Vitiello MV. Growth hormone-releasing hormone improves cognitive function in older adults: sleep on it–reply. JAMA Neurol. 2013;70(4):529-30.
17. Baker, L. D. et al. Effects of growthhormone-releasing hormone on cognitive function in adultswith mild cognitive impairment on healthy older adults.Arch. Neurol. doi:10.1001/archneurol.2012.1970.
18. Available from https://clinicaltrials.gov/ct2/show/NCT02572323.
19. Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-890. doi:10.1001/jamaneurol.2013.1425.
20. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. Published 2017 Jun 15. doi:10.1371/journal.pone.0179538.
21. Maggi P, Di biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17(1):551.
22. Available from https://www.nejm.org/doi/full/10.1056/NEJMoa072375.
23. Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10. PMID: 22495074; PMCID: PMC3348954.
24. Available from https://clinicaltrials.gov/ct2/show/NCT02196831.
25. Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253–2259. doi:10.1097/QAD.0000000000001614.
26. Miller K, Halow J, Koretsky AP. Phosphocreatine protects transgenic mouse liver expressing creatine kinase from hypoxia and ischemia. Am J Physiol. 1993;265(6 Pt 1):C1544-51.
27. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-7.
28. Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol–current therapies and future opportunities. Br J Pharmacol. 2012;167(6):1177–1194. doi:10.1111/j.1476-5381.2012.02081.x.
29. Tuffaha SH, Singh P, Budihardjo JD, et al. Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert OpinTher Targets. 2016;20(10):1259-65.